HUTCHMED’s Lung Cancer Combo Therapy Shows Promising Phase III Results
Event summary
- HUTCHMED will present Phase III data for savolitinib and osimertinib combination therapy at ESMO Congress 2026.
- Two studies (SAFFRON and SANOVO) showed statistically significant improvements in PFS and OS for NSCLC patients.
- SAFFRON results featured in Presidential Symposium, SANOVO in Proffered Paper session.
- ESMO Congress 2026 takes place October 23-27 in Madrid, Spain.
The big picture
HUTCHMED’s presentation at ESMO 2026 underscores the growing importance of targeted combination therapies in oncology. The positive Phase III results for the savolitinib-osimertinib combination position HUTCHMED to compete with established players in the NSCLC space. The strategic partnerships with AstraZeneca and Eli Lilly enhance its commercialization capabilities, particularly in global markets.
What we're watching
- Regulatory Pathway
- Whether the positive Phase III results will accelerate regulatory approval for the savolitinib-osimertinib combination.
- Commercial Strategy
- How HUTCHMED positions this combination therapy in the competitive NSCLC treatment landscape.
- Pipeline Momentum
- The pace at which HUTCHMED advances other combination therapies in its pipeline.
Related topics